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ABSTRACT
Liver metastasis is the major cause of death following a diagnosis of colorectal 
cancer (CRC). In this study, we compared the copy number profiles of paired primary 
and liver metastatic CRC to better understand how the genomic structure of primary 
CRC differs from the metastasis. Paired primary and metastatic tumors from 16 patients 
and their adjacent normal tissue samples were analyzed using single nucleotide 
polymorphism arrays. Genome-wide chromosomal copy number alterations were 
assessed, with particular attention to 188 genes known to be somatically altered in 
CRC and 24 genes that are clinically actionable in CRC. These data were analyzed with 
respect to the timing of primary and metastatic tissue resection and with exposure to 
chemotherapy. The genomic differences between the tumor and paired metastases 
revealed an average copy number discordance of 22.0%. The pairs of tumor samples 
collected prior to treatment revealed significantly higher copy number differences 
compared to post-therapy liver metastases (P = 0.014). Loss of heterozygosity 
acquired in liver metastases was significantly higher in previously treated liver 
metastasis samples compared to treatment naive liver metastasis samples (P = 0.003). 
Amplification of the clinically actionable genes ERBB2, FGFR1, PIK3CA or CDK8 was 
observed in the metastatic tissue of 4 patients but not in the paired primary CRC. These 
examples highlight the intra-patient genomic discrepancies that can occur between 
metastases and the primary tumors from which they arose. We propose that precision 
medicine strategies may therefore identify different actionable targets in metastatic 
tissue, compared to primary tumors, due to substantial genomic differences. 
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INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer worldwide, conferring significant morbidity, 
mortality and cost to the public health system [1]. The 
majority of deaths result from metastasis of the primary 
cancer to distant organs, predominantly the liver [2]. 
The standard first-line chemotherapeutic regimen for 
metastatic CRC is a combination of fluorouracil (5-FU) 
and folinic acid with oxaliplatin (FOLFOX) or irinotecan 
(FOLFIRI) with or without targeted agents [3]. Currently, 
the single molecular targetable treatment available 
for CRC is epidermal growth factor receptor (EGFR) 
inhibitors for tumors lacking mutation in the oncogene 
KRAS [4–6]. However, even among patients with KRAS 
wild type primary tumors, a recent study showed only 10–
20 % of metastatic CRC patients benefitted from an EGFR 
inhibitor [7]. One contributory reason for this low rate of 
response may be discordance in KRAS mutation status 
between primary tumors and corresponding metastases 
[8, 9]. It is also likely for some cases that effector 
molecules downstream of the EGFR, including members 
of the MAPK and AKT signaling pathways [7], may be 
further altered during the metastatic process or following 
therapeutic intervention [10, 11]. Clarification of whether 
it is sufficient to assay the primary tumor or necessary 
to biopsy metastatic deposits for biomarker assessment 
is critical for optimizing management of patients with 
metastatic disease. 
Genome-wide assessment of somatic copy number 
alterations provides opportunities for identifying cancer 
driver genes in an unbiased manner and may provide 
novel markers for the early diagnosis and personalized 
treatment of CRC [12]. For example, DNA copy number 
amplifications in KRAS, ERBB2, MET and FGFR1 
have been found to be predictors of poor prognosis and 
resistance to anti-EGFR therapy for CRC patients [13, 14]. 
It has also been recently shown that DNA copy number 
alterations are major sources of tumor heterogeneity, and 
one study found a striking discordance in copy number 
alterations between paired primary tumors and metastatic 
in samples from 27 patients using a DNA sequencing panel 
which was limited to only 100 genes [15]. Moreover, an 
understanding of the clonal composition of primary tumors 
and the extent to which this contributes to the molecular 
profile of metastatic disease pre- and post-therapy is vital 
to fully realize the potential of genomics in precision 
medicine approaches to improve patient outcomes.
We performed genome-wide chromosomal copy 
number assessment using single nucleotide polymorphism 
(SNP) arrays of primary CRC collected before therapy 
and the paired liver metastasis collected before or after 
therapeutic intervention. We show that copy number 
alterations differ significantly between primary tumors and 
their metastatic deposits.
RESULTS
Clinical and histologic data
Surgical samples of primary colorectal tumors and 
paired liver metastases from 16 patients (Median age 
62.6 years) were analyzed (Table 1). A paired normal 
control sample was obtained for each patient from 
macroscopically normal mucosa adjacent to the primary 
tumor. In all 16 patients, primary CRC tissue was taken 
prior to chemotherapy. Nine patients had a synchronous 
liver metastasis at the time of diagnosis and 7 patients 
developed a liver metastasis metachronously (Figure 1). 
Metastatic tissue was taken after exposure to chemotherapy 
in 6 patients, which included 5 metachronous patients and 
1 synchronous patient who had neoadjuvant chemotherapy 
prior to liver surgery (Figure 1). 
KRAS mutational discordance between primary and 
paired metastatic tumors was identified in 2 patients (2/16, 
13%), whilst BRAF mutation was concordant in the single 
patient with a BRAF mutant allele (Table 2). These two 
patients both had Stage III metachronous disease and had 
received adjuvant chemotherapy prior to sampling of the 
metastasis. Loss of MLH1 immunostaining, indicating a 
likely mismatch DNA repair deficiency and microsatellite 
instability, was detected in 3/16 patients (18.8 %, Table 2) 
and was concordant between all primary tumors and 
paired metastases (Supplementary Figure 1). 
Differences between copy number and LOH 
profiles for each primary tumor and metastasis 
pair including the influence of chemotherapy 
exposure
We calculated the proportion of each genome that 
was affected by a copy number change from the normal 
diploid state. Within the 32 samples, the proportion of copy 
number altered genome ranged from 16.1% to 100%. In 16 
samples, over 80% of the genome was copy number altered. 
Recent studies revealed that whole-genome duplication 
(WGD) events occur frequently during tumorigenesis and 
metastasis, resulting in cells bearing complex karyotypes 
[16, 17]. WGD was identified in both the primary tumor 
and metastasis in 4 pairs (C2, C12, C14 and C15) whereas 
in a further 5 pairs only the metastasis had undergone WGD 
(C3, C8, C11, C13 and C16. Figure 2A). There were no 
patients in whom only the primary tumor had undergone 
WGD. WGD was not significantly associated with 
synchronous versus metachronous disease state, or with 
treated versus treatment naive metastases.
Copy number alterations may result in shifts in 
the allelic ratio from the normal heterozygous state 
through to regions of loss of heterozygosity (LOH) that 
can occur at any copy number and is measured as the B 
allele frequency in the array data. For all sample pairs 
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Table 1: Clinicopathological characteristics of the 16 patients with CRC
Case 
No. Age Sex
* Location
CRC 
size 
(cm)
Invasion 
depth^ pN-factor
pStage at 
diagnosis
  Adjuvant/
Neoadjuvant 
chemotherapy #
 
Chemotherapy 
for metastasis#
2nd 
chemotherapy#
Liver Metastasis 
Synchronous/
Metachronous 
with Primary
Outcome 
(months)
C1 67 F Right side 3.6 SS 2 III XELOX XELOX Metachronous dead (37)
C2 57 F Left side 4.0 SS 2 III UFT+ LV UFT+ LV Metachronous dead (56)
C3 74 M Right side 5.5 SI 2 III XELOX XELOX Metachronous dead (27)
C4 63 F Rectum 8.0 SE 3 IV mFOLFOX6 FOLFIRI Metachronous dead (28)
C5 64 M Right side 7.0 SS 2 IV XELOX+Bev XELOX+Bev Synchronous alive (36)
C6 78 M Rectum 6.0 SS 1 III mFOLFOX6 FOLFIRI Metachronous dead (42)
C7 58 F Rectum 3.0 SS 0 II None mFOLFOX6 FOLFIRI Metachronous dead (70)
C8 60 M Left side 2.8 MP 0 II None TS1 Metachronous alive (96)
C9 69 M Rectum 4.6 SS 0 IV None mFOLFOX6+ 
Bev
Synchronous alive (15)
C10 47 F Right side 6.0 SE 3 IV None None Synchronous dead (5)
C11 69 M Left side 6.0 SS 0 IV None XELOX+Bev mFOLFOX6+ 
Bev
Synchronous alive (37)
C12 52 F Rectum 5.0 SS 3 IV None mFOLFOX6 Synchronous alive (84)
C13 41 M Rectum 5.0 A 2 IV None XELOX IRIS+Bev Synchronous dead (31)
C14 73 M Right side 7.0 SS 2 IV None None Synchronous dead (71)
C15 58 M Left side 3.0 SS 1 IV None UFT+ LV Synchronous alive (102)
C16 72 M Left side 4.8 SS 0 IV None mFOLFOX6 Synchronous alive (12)
*M–male; F–female   para aortic lymph node metastasis
^SS–Tumor invades through the muscularis propria into pericolorectal tissue; SI–tumor directly invades or is adherent to other organs or structures; 
SE–tumor penetrates to the surface of the visceral peritoneum; MP–tumor invades muscularis propria; A–rectal tumor invades through the muscularis propria into 
pericolorectal tissue
#XELOX–Capecitabine and oxaliplatin; UFT+ LV–uracil-tegafur plus leucovorin; mFOLFOX6–fluorouracil (5-FU) and leucovorin with oxaliplatin; 
FOLFIRI–5-FU and leucovorin with irinotecan; Bev–bevacizumab; TS1–Oral fluoropyrimidine anticancer drug; IRIS–irinotecan and TS-1.
Figure 1:  Clinical characteristics of the study cohort. The course of treatment for the 16 CRC patients is indicated schematically. 
Samples were obtained at surgical resection time points indicated by yellow blocks for primary CRC and red blocks for the liver metastases. 
The survival status of the patient is shown, through observations made at 1–6 month intervals until death or December 2015.
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excluding from patient C6, the proportion of the tumor 
genome affected by LOH was similar between primary 
and metastatic tumors even when only the metastasis had 
undergone WGD (Figure 2B). 
A comparative analysis was carried out to assess 
the differences in copy number states between the 
paired samples. Each genome was segmented into 
10Kb regions and the copy number state was compared 
between corresponding regions in the paired primary 
and metastasis samples. Initially, in the 5 pairs of 
samples displaying WGD in only the metastasis, the 
genomes appeared highly different in metastases 
compared to matched primary tumors. On further 
examination, the majority of the differences were due 
an increase of 2 copies without a change in the LOH 
status. This large scale moderate copy number increase 
with no selection for one of the alleles is unlikely to 
result in driver gene expression changes relative to the 
background genes, therefore a correction for the WGD 
was applied. All regions where the copy number change 
difference was either +1 or +2 copies without LOH were 
recorded as no difference or concordant between paired 
samples. With the WGD correction applied, the average 
percent copy number discordance across all pairs of 
samples was 22.0% (range 3.3 – 63.6). Interestingly, 
the treatment naive tumor sample pairs had significantly 
higher copy number differences compared to sample 
pairs where the metastasis had been collected post-
therapy (Figure 3A, P = 0.014). LOH events unique 
to primary samples occurred more frequently in those 
that had not been exposed to therapy, whilst LOH 
events unique to metastatic tumors was more frequent 
post-therapy (Figure 3B, P = 0.003). Overall the LOH 
patterns between the paired tumors were different by 
an average 12.4% of the genome (ranging from 2.0% to 
35.6%, Figure 3B).  
Differences in candidate driver genes between 
primary and metastasis samples
We analyzed the copy number status for 188 
candidate CRC genes in the paired primary tumors and 
metastases (Supplementary Table 1). The copy number 
status of 123 genes (123/188, 65.4%) was shared between 
primary tumor and metastasis (Figure 4A). These included 
genes recurrently mutated in colorectal cancer such as 
APC, TP53, KRAS, EGFR, SMAD4, FBXW7, NRAS, 
VEGFA and RNF43. The genes affected most frequently 
by discordant copy number status between primary and 
paired metastatic tissues were CSMD3, TRPS1, TGFBR2, 
CTNNB1, FHIT and MACROD2 (Table 3). TGFBR2, 
CTNNB1 and FHIT are located on chromosome 3, which 
was amplified only in metastases (3/16, 18.8 %).
An example of mutational discordance is shown 
in Figure 4B where KRAS mutation was detected in the 
primary tumor, which would have rendered the patient 
ineligible for anti-EGFR therapy. However, the paired 
liver metastasis was wild type for KRAS. The KRAS locus 
Table 2: Tumor purity and KRAS/BRAF/mismatch repair status in primary and paired metastasis
Case No. PurityPT
Purity
Met
KRAS
PT
KRAS
Met
BRAF
PT
BRAF
Met
Mismatch Repair
PT
Mismatch Repair
Met
C1 0.72 0.95 Mutant Mutant wt wt MSS MSS
C2 0.87 0.88 wt Mutant wt wt MLH1 Loss MLH1 Loss
C3 0.54 0.82 Mutant Mutant wt wt MSS MSS
C4 0.63 0.78 wt wt wt wt MSS MSS
C5 0.82 0.90 wt wt wt wt MSS MSS
C6 0.64 0.92 Mutant wt wt wt MSS MSS
C7 0.68 0.56 wt wt wt wt MLH1 Loss MLH1 Loss
C8 0.70 0.98 wt wt wt wt MSS MSS
C9 0.78 0.85 wt wt wt wt MSS MSS
C10 0.90 0.75 wt wt Mutant Mutant MSS MSS
C11 0.76 0.97 wt wt wt wt MSS MSS
C12 0.92 0.96 wt wt wt wt MSS MSS
C13 0.62 0.76 Mutant Mutant wt wt MLH1 Loss MLH1 Loss
C14 0.90 0.88 Mutant Mutant wt wt MSS MSS
C15 0.77 0.91 wt wt wt wt MSS MSS
C16 0.73 0.79 Mutant Mutant wt wt MSS MSS
PT: primary tumors Met: metastasis, wt: Wildtype, MSS: Microsatellite Stable. 
Tumor purity was determined from SNP array data using qPure38.
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Figure 2: Differences between the copy number profiles of each tumor and metastasis pair including the influence of 
chemotherapy exposure. The proportion of tumor genomes affected by copy number alteration and loss of heterozygosity (LOH) is 
shown for paired primary tumors (T) and metastases (M) from the 16 cases. The level of loss or gain of DNA is indicated by different colors 
(A). Whole genome duplication (WGD) is indicated by black triangles above the bar and is defined as >70% of at least half the chromosomes 
display copy numbers between 3 and 4 with both parental alleles present. The proportion of tumor genome with LOH is plotted (B).
Figure 3: Genomic copy number and loss of heterozygosity (LOH) differences identified between all 16 primary tumor 
and metastasis pairs. The copy number and LOH was assayed every 10Kb for 287921 sites per metastatic genome and compared with 
the corresponding region in the paired primary tumor sample with a correction for whole genome duplication applied to all sample pairs. 
The proportion of regions with copy number that was different between the paired samples is indicated in (A) by the height of the green 
bars. The proportion of regions for which LOH was observed only in the metastasis sample is indicated by the height of the dark blue 
bars and those with LOH only in the primary tumor sample by the height of the light blue sections (B). In both charts the grey indicates 
concordant copy number or LOH states between the paired samples. *P < 0.05, **P < 0.01 (t-test).
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was heterozygous in the primary tumor but showed copy 
neutral LOH in the paired metastasis, suggesting deletion 
of the mutant allele in the metastatic tumor. 
Copy number status for genes with clinically 
available targeted agents
The copy number status of 24 genes known to be 
clinically actionable in colorectal cancer [18, 19] were 
assessed for amplification occurring specifically in the 
metastasis but not the primary tumor, as these alterations 
may have been clinically useful in informing therapy 
selection. A subset of these can be targeted by therapies 
that are already approved or in late-phase development 
(Phase II or III). These include members of the RTK 
and RAS pathways, such as KRAS, BRAF, NRAS, and 
ERBB2, which have known associated with resistance 
to anti-EGFR targeted therapies [13]. In our study, 
amplification of ERBB2, FGFR1, PIK3CA or CDK8 loci 
was observed in metastatic but not the paired primary 
tumors of patients C6, C8, C13 and C16, respectively 
(Figure 5). ERBB2 encodes HER2, which is the target of 
trastuzumab. ERBB2 was amplified only in the metastasis 
of patient C6, therefore trastuzumab may have been 
beneficial this patient following relapse from standard 
chemotherapy. Similarly, FGFR1, a target of regorafenib, 
was specifically amplified only in the metastasis of 
patient C8 (Figure 5). 
DISCUSSION
The significant morbidity of colorectal cancer is 
largely due to metastatic dissemination of the primary 
tumor. These distant metastatic deposits may have a very 
different molecular landscape to the primary disease as 
they may have arisen from minor clones of the primary 
disease or have undergone molecular changes through 
selective pressures during the metastatic process. 
However, actionable biomarkers used for informing 
therapeutic regimens for metastatic disease are usually 
based on the molecular status of the primary tumor 
sample alone. Here, we performed SNP arrays to 
investigate copy number profiles between paired primary 
and metastatic colorectal cancer samples to better 
understand the global differences that may occur between 
these two disease states.
When comparing the primary tumors to paired 
metastatic samples, almost a quarter (22.0%) of the 
genomes contained copy number differences. Whole 
genome duplication occurred in 4 primary tumors and 
their paired metastases. In another 5 paired samples, 
Figure 4:  Differences in candidate driver genes between primary and metastasis samples. We analysed the copy number 
status for 188 candidate CRC genes in the paired primary CRC and metastases (A). The copy number status of 123 genes (123/188 
65.4%) was shared between primary and metastasis. KRAS mutation was present in the primary cancers but was not detectable in the 
metastatic sample following chemotherapy (B). The copy number profile of the genomic region containing KRAS indicates the locus was 
heterozygous (2 copies; AB) in the primary tumor but showed copy neutral LOH (2 copies; AA) in the paired metastasis (B). 
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WGD was identified in the metastasis but not in the 
primary tumor. There were no paired samples where 
only the primary tumor had undergone WGD. A recent 
report revealed that the majority (62.5%) of esophageal 
adenocarcinoma undergo WGD and that tumors with 
WGD had different patterns of genomic alterations 
with more frequent oncogenic amplifications and 
less frequent inactivation of tumor suppressors [20]. 
Dewhurst et al. showed that in colorectal cancer, WGD 
allows for a higher rate of chromosomal instability, 
resulting in poor relapse-free survival [21]. These 
studies are consistent with our finding of greater 
rates of WGD in metastases compared to primary 
tumours. Further studies are now required to determine 
whether WGD is associated with distinctive clinical or 
molecular features.
In colorectal cancer patients with liver metastases, 
it has recently been reported that intra-tumoral 
heterogeneity is more common in patients previously 
exposed to chemotherapy compared with patients who 
are chemotherapy-naive [22]. A similar finding is seen 
in patients with urothelial carcinoma metastases [23]. 
Understanding how selective pressure from chemotherapy 
is involved in evolution from primary tumor to metastasis 
is a central biological question with clinical implications. 
In our study, LOH events unique to the primary tumor 
were commonly observed in therapy naive cases, which 
likely reflects the reduced clonal complexity of the 
secondary tumor due to the metastasis and expansion of a 
single primary tumor clone. By contrast, we predominantly 
observed an acquisition of LOH events in metastases 
following chemotherapy, suggesting the therapy has 
driven the increase in genomic complexity. 
For colorectal cancer, the mutation status of KRAS 
and BRAF in is critical for directing choice of therapy. 
Here we have demonstrated a case where the primary 
Figure 5: Copy number status private to the metastasis sample affecting clinically actionable targets. The degree of copy 
number difference was calculated by subtraction of the primary tumor copy number state from that of the liver metastasis. The copy number 
status of 24 clinically actionable genes was assessed for alterations occurring specifically in metastatic but not primary tissue. ERBB2, 
a known target receptor of trastuzumab (anti-HER2), was specifically amplified only in the metastatic tissue of C6. Similarly, FGFR1, a 
known target receptor of regorafenib was specifically amplified only in the metastatic tissue of C8. Black arrow indicates specific gene 
amplification of C6 (ERBB2) and C8 (FGFR1) respectively.
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tumor was KRAS mutant but was wildtype in the metastatic 
sample following chemotherapy. This suggests that the 
mutant allele was either lost from the metastatic tumor or 
the metastatic deposit arose from a KRAS wildtype clone 
in the primary tumor and highlights the importance of 
assessing clinically actionable markers in the metastatic 
rather than primary tumor sample. In this case, targeting 
the metastatic disease with an anti-EGFR agent may have 
improved the outcome for this patient.  
Our data provide a strong rationale for investigating 
copy number variations throughout the genome to identify the 
full complement of potentially actionable genomic alterations 
that could be developed as clinical biomarkers or therapeutic 
targets. Amplifications may give rise to overexpression of 
oncoproteins that are targets of currently available drugs. We 
hypothesized that genes in regions of altered copy number 
would include known targets for currently available drugs that 
may be of benefit in the management of individual patients. 
We did find a number of examples including amplification 
private to the metastasis at loci for genes including ERBB2, 
FGFR1, CDK8 and PIK3CA, which may have increased 
sensitivity to trastuzumab [24], regorafenib [25], flavopiridol 
[26], or PI3K/AKT/mTOR inhibitor, respectively (Figure 
5). These metastasis-specific gene amplifications are at 
present insufficient to guide patient management. However, 
this demonstrates there are potentially actionable changes 
that occur exclusively in the metastatic tumor but not in the 
primary tumor.
Studies in lung, gastric, urothelial, thyroid and 
breast cancer have demonstrated somatic copy number 
discordance between primary tumors and their metastases 
[27–31]. Consistent with our results, these studies reported 
a high rate of concordance when examining known driver 
mutations or copy number alterations. In CRC, a recent 
report from Mamlouk is in line with these findings, 
however, they additionally validated cases of discordance 
in MMP17, TCF7L2, GNAS, CARD11 and TP53 at the 
level of gene copy number [15].
Here we provide proof of concept that metastatic 
samples can be substantially different from their 
matched primary tumors, even prior to chemotherapeutic 
intervention. Understanding intra-tumoral heterogeneity 
is clinically important because it could underlie failure 
of targeted systemic therapy. Further studies using more 
comprehensive approaches such as whole-genome 
sequencing will be needed to characterize all relevant 
classes of mutations, including single nucleotide variations, 
indels, copy number and structural rearrangements and 
non-protein coding mutations with regulatory significance 
between paired primary and metastatic cancers. 
In conclusion, our results demonstrate that the 
molecular discordance between primary and metastatic 
tissue may be of clinical relevance in the era of genomically 
directed precision colorectal cancer medicine. Our data 
suggest that clinically actionable molecular targets for 
metastatic chemotherapy may be missed when relying only 
on biopsies of the primary tumor at the time of diagnosis. 
These differences could be driven by clonal evolution of the 
primary tumor due to the metastatic process or as a result 
of therapy. Serial metastatic or liquid biopsies obtained 
during the course of clinical care may improve outcomes by 
more accurately capturing the rapidly changing molecular 
Table 3: Candidate gene list summarized to highlight differences in the copy number 
Gene Chromosome Amplification private to metastasis Loss private to metastasis
CSMD3 8 3/16 (18.8 %) 1/16 (6.3 %)
TRPS1 8 3/16 (18.8 %) 1/16 (6.3 %)
TGFBR2 3 3/16 (18.8 %) 0/16 (0 %)
CTNNB1 3 3/16 (18.8 %) 0/16 (0 %)
FHIT 3 3/16 (18.8 %) 0/16 (0 %)
MACROD2 20 0/16 (0 %) 3/16 (18.8 %)
RBFOX1 16 0/16 (0 %) 2/16 (12.5 %)
PTK2 8 2/16 (12.5 %) 2/16 (12.5 %)
VPS13B 8 2/16 (12.5 %) 1/16 (6.3 %)
IRS2 13 2/16 (12.5 %) 1/16 (6.3 %)
CBLB 3 2/16 (12.5 %) 0/16 (0 %)
KALRN 3 2/16 (12.5 %) 0/16 (0 %)
WHSC1L1 8 2/16 (12.5 %) 0/16 (0 %)
FGFR1 8 2/16 (12.5 %) 0/16 (0 %)
MYC 8 2/16 (12.5 %) 0/16 (0 %)
Colorectal cancer candidate genes are reported where copy number differences were observed between the paired samples 
for at least 2 cases.
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landscape of a given patient’s disease to better rationalize 
strategies for personalized therapy.
MATERIALS AND METHODS
Human tissue samples
Samples from 16 patients who had undergone radical 
surgery for colorectal carcinoma between 2003 and 2014 
at Hokkaido University Hospital were analyzed in this 
study. A total of 48 tissue samples from these 16 patients 
were obtained in a fresh state including from normal 
colorectal mucosa, primary tumors and the associated 
colorectal liver metastases. All tumors were snap frozen in 
liquid nitrogen within 20 minutes of extirpation. Normal 
tissue was sampled at least 10cm from the tumor margin. 
Clinicopathological information for the study patients is 
summarized in Table 1. Clinical staging and grading of liver 
metastases were based on the definition set by the Japanese 
Society for Cancer of Colon and Rectum Guidelines [32]. 
Patients were observed at 1–6 month intervals until death 
or December 2015. All patients provided written, informed 
consent. Approval was obtained from the Hokkaido 
University Human Research Ethics Committee (HREC) 
(14-005) and the QIMR Berghofer HREC (P2139). Nucleic 
acids were extracted using the Qiagen Allprep Kit in 
accordance with the manufacturer’s instruction. DNA was 
quantified using Qubit HS DNA Assay (Invitrogen). 
Clinical gene hotspot mutation testing
The presence of the BRAF V600E and KRAS 
codon 12 and 13 mutations were detected using allelic 
discrimination or high resolution melta analysis, 
respectively, as described previously [33–35]. Putative 
mutations were confirmed by Sanger sequencing.
Immunohistochemical evaluation
Formalin-fixed paraffin-embedded tissue blocks 
were prepared from surgical specimens, and sections were 
stained with hematoxylin and eosin for histopathological 
examination by two gastrointestinal pathologists. 
Immunohistochemical staining for MLH1 was performed 
as described previously [36]. In brief, 4µM sections were 
cut, dewaxed and rehydrated. High pH antigen retrieval 
solution (pH 9.0; Dako, Glostrup, Denmark) was used 
for MLH1 at 112°C for 7 min. All sections were stained 
using the MLH1 antibody (clone G168-15, 1:100; BD 
Pharmingen). Loss of MLH1 expression was recorded 
when nuclear staining was observed in normal tissue but 
not in adjacent malignant cells. 
SNP arrays and copy number analysis
DNA from all samples was assayed with the 
Omni 2.5–8, V1.0 and V1.1 IlluminaBeadChips as per 
manufacturer’s instructions (Illumina). SNP arrays were 
scanned on an iScan (Illumina), data was processed 
using the Genotyping module (v.1.9.4) in GenomeStudio 
v.2011.1 (Illumina) to calculate B-allele frequencies 
(BAF) and logR ratios. GAP [37] software was used 
to segment the SNP array data and determine the level 
of copy number which was classified into one of 5 
categories: homozygous deletion (copy number: 0), loss 
(copy number:1), copy neutral LOH (copy number:2), 
gain (copy number: 3–5) and amplification (copy number: 
6–8). Loss of heterozygosity segments were generated 
using the segmented B-allele frequency data. Tumor 
cellularity was determined from SNP array data using 
qPure [38] to ensure a minimum tumor cellularity of 50%. 
Whole genome duplication (WGD) whereby >70% of at 
least half the chromosomes display copy numbers between 
3 and 4 with both parental alleles present that typically 
totaled >45% of all genomic copy number (Supplementary 
Table 2). All array data has been deposited into the NCBI 
Gene Expression Omnibus (GEO) repository under 
accession GSE100787.
Identification of discordant copy number and/or 
LOH between the sample pairs
A pair wise comparison analysis of genomic copy 
number and heterozygosity states over 10Kb windows 
for each primary and liver metastasis pair was carried 
out. The copy number and heterozygosity for each 10Kb 
was determined by the largest segment in that region 
identified using the GAP tool. Discordant copy number 
regions were identified by subtraction of the primary 
tumor copy number from that of the liver metastasis. 
To account for WGD inflating the number of discordant 
regions, all regions where the copy number change 
difference was either +1 or +2 copies without LOH were 
recorded as no difference or concordant between paired 
samples. Discordant regions of loss of heterozygosity 
were sought separately and classified into: unchanged; 
loss of heterozygosity in the liver metastasis; or retained 
heterozygosity in the liver metastasis. The genomic 
proportion of these discordant regions, that were made 
up of single or multiple adjacent 10Kb regions, was 
recorded.
Genome-wide profiling of potential related genes
We sought to investigate the copy number state 
of 188 genes (listed in Supplementary Table 1) which 
were previously identified as significantly mutated genes 
in CRC [12, 15], and reported by The Cancer Genome 
Atlas (TGGA) [19] as well as the Catalogue of Somatic 
Mutations in Cancer (COSMIC) [39]. Copy number and 
LOH status for each gene was determined by the largest 
segment produced using GAP, within or spanning the 
gene footprint (from transcription start site to the last base 
of the longest transcript). Differences in copy number, 
Oncotarget3403www.impactjournals.com/oncotarget
heterozygosity status and segment boundaries between 
tumor pairs were summed across the patients.
Statistical analysis
Two-tailed student’s t-tests were used to compare 
differences between groups. All differences were 
considered significant at a p-value of less than 0.05. 
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